BioMarin discontinues rare disease drug; CSL and Arcturus split up

BioMarin drops BMN401; CSL & Arcturus end mRNA pact with $12M payment; Bavarian Nordic's Imvanex approved for children aged 2-11 in EU.

Raccontata daendpoints.news